Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 76

1.

Monitoring dynamic cytotoxic chemotherapy response in castration-resistant prostate cancer using plasma cell-free DNA (cfDNA).

Patsch K, Matasci N, Soundararajan A, Diaz P, Agus DB, Ruderman D, Gross ME.

BMC Res Notes. 2019 May 15;12(1):275. doi: 10.1186/s13104-019-4312-2.

2.

Correlating nuclear morphometric patterns with estrogen receptor status in breast cancer pathologic specimens.

Rawat RR, Ruderman D, Macklin P, Rimm DL, Agus DB.

NPJ Breast Cancer. 2018 Sep 4;4:32. doi: 10.1038/s41523-018-0084-4. eCollection 2018.

3.

Future cancer research priorities in the USA: a Lancet Oncology Commission.

Jaffee EM, Dang CV, Agus DB, Alexander BM, Anderson KC, Ashworth A, Barker AD, Bastani R, Bhatia S, Bluestone JA, Brawley O, Butte AJ, Coit DG, Davidson NE, Davis M, DePinho RA, Diasio RB, Draetta G, Frazier AL, Futreal A, Gambhir SS, Ganz PA, Garraway L, Gerson S, Gupta S, Heath J, Hoffman RI, Hudis C, Hughes-Halbert C, Ibrahim R, Jadvar H, Kavanagh B, Kittles R, Le QT, Lippman SM, Mankoff D, Mardis ER, Mayer DK, McMasters K, Meropol NJ, Mitchell B, Naredi P, Ornish D, Pawlik TM, Peppercorn J, Pomper MG, Raghavan D, Ritchie C, Schwarz SW, Sullivan R, Wahl R, Wolchok JD, Wong SL, Yung A.

Lancet Oncol. 2017 Nov;18(11):e653-e706. doi: 10.1016/S1470-2045(17)30698-8. Epub 2017 Oct 31. Review.

4.

Safety and Efficacy of Docetaxel, Bevacizumab, and Everolimus for Castration-resistant Prostate Cancer (CRPC).

Gross ME, Dorff TB, Quinn DI, Diaz PM, Castellanos OO, Agus DB.

Clin Genitourin Cancer. 2017 Jul 14. pii: S1558-7673(17)30200-8. doi: 10.1016/j.clgc.2017.07.003. [Epub ahead of print]

PMID:
28826933
5.

Design and rationale for the Influenza vaccination After Myocardial Infarction (IAMI) trial. A registry-based randomized clinical trial.

Fröbert O, Götberg M, Angerås O, Jonasson L, Erlinge D, Engstrøm T, Persson J, Jensen SE, Omerovic E, James SK, Lagerqvist B, Nilsson J, Kåregren A, Moer R, Yang C, Agus DB, Erglis A, Jensen LO, Jakobsen L, Christiansen EH, Pernow J.

Am Heart J. 2017 Jul;189:94-102. doi: 10.1016/j.ahj.2017.04.003. Epub 2017 Apr 18.

6.

JUN-Mediated Downregulation of EGFR Signaling Is Associated with Resistance to Gefitinib in EGFR-mutant NSCLC Cell Lines.

Kani K, Garri C, Tiemann K, Malihi PD, Punj V, Nguyen AL, Lee J, Hughes LD, Alvarez RM, Wood DM, Joo AY, Katz JE, Agus DB, Mallick P.

Mol Cancer Ther. 2017 Aug;16(8):1645-1657. doi: 10.1158/1535-7163.MCT-16-0564. Epub 2017 May 31.

7.

The Long-Term Benefits of Increased Aspirin Use by At-Risk Americans Aged 50 and Older.

Agus DB, Gaudette É, Goldman DP, Messali A.

PLoS One. 2016 Nov 30;11(11):e0166103. doi: 10.1371/journal.pone.0166103. eCollection 2016.

8.

Single cell dynamic phenotyping.

Patsch K, Chiu CL, Engeln M, Agus DB, Mallick P, Mumenthaler SM, Ruderman D.

Sci Rep. 2016 Oct 6;6:34785. doi: 10.1038/srep34785.

9.

Quantifying differences in cell line population dynamics using CellPD.

Juarez EF, Lau R, Friedman SH, Ghaffarizadeh A, Jonckheere E, Agus DB, Mumenthaler SM, Macklin P.

BMC Syst Biol. 2016 Sep 21;10(1):92.

10.

A high-content image-based method for quantitatively studying context-dependent cell population dynamics.

Garvey CM, Spiller E, Lindsay D, Chiang CT, Choi NC, Agus DB, Mallick P, Foo J, Mumenthaler SM.

Sci Rep. 2016 Jul 25;6:29752. doi: 10.1038/srep29752.

11.

A Plasma-Based Protein Marker Panel for Colorectal Cancer Detection Identified by Multiplex Targeted Mass Spectrometry.

Jones JJ, Wilcox BE, Benz RW, Babbar N, Boragine G, Burrell T, Christie EB, Croner LJ, Cun P, Dillon R, Kairs SN, Kao A, Preston R, Schreckengaust SR, Skor H, Smith WF, You J, Hillis WD, Agus DB, Blume JE.

Clin Colorectal Cancer. 2016 Jun;15(2):186-194.e13. doi: 10.1016/j.clcc.2016.02.004. Epub 2016 Mar 25.

12.

Intracellular kinetics of the androgen receptor shown by multimodal Image Correlation Spectroscopy (mICS).

Chiu CL, Patsch K, Cutrale F, Soundararajan A, Agus DB, Fraser SE, Ruderman D.

Sci Rep. 2016 Mar 3;6:22435. doi: 10.1038/srep22435.

13.

THE DOCTOR WILL SEE YOU (AND YOUR DATA) NOW.

Agus DB.

Fortune. 2016 Jan 1;173(1):90-3. No abstract available.

PMID:
26875351
14.

Stochasticity and determinism in cancer creation and progression.

Davies PC, Agus DB.

Converg Sci Phys Oncol. 2015 Dec;1(2). pii: 026003. doi: 10.1088/2057-1739/1/2/026003. Epub 2016 Jan 7. No abstract available.

15.

The Impact of Microenvironmental Heterogeneity on the Evolution of Drug Resistance in Cancer Cells.

Mumenthaler SM, Foo J, Choi NC, Heise N, Leder K, Agus DB, Pao W, Michor F, Mallick P.

Cancer Inform. 2015 Jul 15;14(Suppl 4):19-31. doi: 10.4137/CIN.S19338. eCollection 2015.

16.

Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel-prednisone in metastatic castration-resistant prostate cancer.

Petrylak DP, Gandhi JG, Clark WR, Heath E, Lin J, Oh WK, Agus DB, Carthon B, Moran S, Kong N, Suri A, Bargfrede M, Liu G.

Invest New Drugs. 2015 Apr;33(2):397-408. doi: 10.1007/s10637-014-0199-x. Epub 2015 Jan 4.

17.

Intolerance of uncertainty, cognitive complaints, and cancer-related distress in prostate cancer survivors.

Eisenberg SA, Kurita K, Taylor-Ford M, Agus DB, Gross ME, Meyerowitz BE.

Psychooncology. 2015 Feb;24(2):228-35. doi: 10.1002/pon.3590. Epub 2014 Jun 2.

PMID:
24891013
18.

Phase I/II trial of orteronel (TAK-700)--an investigational 17,20-lyase inhibitor--in patients with metastatic castration-resistant prostate cancer.

Dreicer R, MacLean D, Suri A, Stadler WM, Shevrin D, Hart L, MacVicar GR, Hamid O, Hainsworth J, Gross ME, Shi Y, Webb IJ, Agus DB.

Clin Cancer Res. 2014 Mar 1;20(5):1335-44. doi: 10.1158/1078-0432.CCR-13-2436. Epub 2014 Jan 13.

19.

A physical sciences network characterization of non-tumorigenic and metastatic cells.

Physical Sciences - Oncology Centers Network, Agus DB, Alexander JF, Arap W, Ashili S, Aslan JE, Austin RH, Backman V, Bethel KJ, Bonneau R, Chen WC, Chen-Tanyolac C, Choi NC, Curley SA, Dallas M, Damania D, Davies PC, Decuzzi P, Dickinson L, Estevez-Salmeron L, Estrella V, Ferrari M, Fischbach C, Foo J, Fraley SI, Frantz C, Fuhrmann A, Gascard P, Gatenby RA, Geng Y, Gerecht S, Gillies RJ, Godin B, Grady WM, Greenfield A, Hemphill C, Hempstead BL, Hielscher A, Hillis WD, Holland EC, Ibrahim-Hashim A, Jacks T, Johnson RH, Joo A, Katz JE, Kelbauskas L, Kesselman C, King MR, Konstantopoulos K, Kraning-Rush CM, Kuhn P, Kung K, Kwee B, Lakins JN, Lambert G, Liao D, Licht JD, Liphardt JT, Liu L, Lloyd MC, Lyubimova A, Mallick P, Marko J, McCarty OJ, Meldrum DR, Michor F, Mumenthaler SM, Nandakumar V, O'Halloran TV, Oh S, Pasqualini R, Paszek MJ, Philips KG, Poultney CS, Rana K, Reinhart-King CA, Ros R, Semenza GL, Senechal P, Shuler ML, Srinivasan S, Staunton JR, Stypula Y, Subramanian H, Tlsty TD, Tormoen GW, Tseng Y, van Oudenaarden A, Verbridge SS, Wan JC, Weaver VM, Widom J, Will C, Wirtz D, Wojtkowiak J, Wu PH.

Sci Rep. 2013;3:1449. doi: 10.1038/srep01449.

20.

Perspective: Meeting of minds.

Agus DB, Gell-Mann M.

Nature. 2012 Nov 22;491(7425):S61. No abstract available.

PMID:
23320291
21.

A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors.

Gordon MS, Mendelson DS, Gross M, Uttenreuther-Fischer M, Ould-Kaci M, Zhao Y, Stopfer P, Agus DB.

Invest New Drugs. 2013 Apr;31(2):409-16. doi: 10.1007/s10637-012-9904-9. Epub 2012 Dec 15.

22.

Reframe the health debate.

Agus DB.

Fortune. 2012 Oct 29;166(7):22. No abstract available.

PMID:
23156666
23.

A cross-platform toolkit for mass spectrometry and proteomics.

Chambers MC, Maclean B, Burke R, Amodei D, Ruderman DL, Neumann S, Gatto L, Fischer B, Pratt B, Egertson J, Hoff K, Kessner D, Tasman N, Shulman N, Frewen B, Baker TA, Brusniak MY, Paulse C, Creasy D, Flashner L, Kani K, Moulding C, Seymour SL, Nuwaysir LM, Lefebvre B, Kuhlmann F, Roark J, Rainer P, Detlev S, Hemenway T, Huhmer A, Langridge J, Connolly B, Chadick T, Holly K, Eckels J, Deutsch EW, Moritz RL, Katz JE, Agus DB, MacCoss M, Tabb DL, Mallick P.

Nat Biotechnol. 2012 Oct;30(10):918-20. doi: 10.1038/nbt.2377. No abstract available.

24.

Anterior gradient 2 (AGR2): blood-based biomarker elevated in metastatic prostate cancer associated with the neuroendocrine phenotype.

Kani K, Malihi PD, Jiang Y, Wang H, Wang Y, Ruderman DL, Agus DB, Mallick P, Gross ME.

Prostate. 2013 Feb 15;73(3):306-15. doi: 10.1002/pros.22569. Epub 2012 Aug 21.

PMID:
22911164
25.

Body image predicts quality of life in men with prostate cancer.

Taylor-Ford M, Meyerowitz BE, D'Orazio LM, Christie KM, Gross ME, Agus DB.

Psychooncology. 2013 Apr;22(4):756-61. doi: 10.1002/pon.3063. Epub 2012 Mar 15.

PMID:
22422671
26.

Quantitative proteomic profiling identifies protein correlates to EGFR kinase inhibition.

Kani K, Faca VM, Hughes LD, Zhang W, Fang Q, Shahbaba B, Luethy R, Erde J, Schmidt J, Pitteri SJ, Zhang Q, Katz JE, Gross ME, Plevritis SK, McIntosh MW, Jain A, Hanash S, Agus DB, Mallick P.

Mol Cancer Ther. 2012 May;11(5):1071-81. doi: 10.1158/1535-7163.MCT-11-0852. Epub 2012 Mar 12.

27.

Safety and pharmacokinetics of high-dose gefitinib in patients with solid tumors: results of a phase I study.

Gross ME, Leichman L, Lowe ES, Swaisland A, Agus DB.

Cancer Chemother Pharmacol. 2012 Jan;69(1):273-80. doi: 10.1007/s00280-011-1757-y. Epub 2011 Oct 15.

PMID:
22002543
28.

Evolutionary modeling of combination treatment strategies to overcome resistance to tyrosine kinase inhibitors in non-small cell lung cancer.

Mumenthaler SM, Foo J, Leder K, Choi NC, Agus DB, Pao W, Mallick P, Michor F.

Mol Pharm. 2011 Dec 5;8(6):2069-79. doi: 10.1021/mp200270v. Epub 2011 Oct 25.

29.

Impact of protein stability, cellular localization, and abundance on proteomic detection of tumor-derived proteins in plasma.

Fang Q, Kani K, Faca VM, Zhang W, Zhang Q, Jain A, Hanash S, Agus DB, McIntosh MW, Mallick P.

PLoS One. 2011;6(7):e23090. doi: 10.1371/journal.pone.0023090. Epub 2011 Jul 29.

30.

Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors.

Robbins CM, Tembe WA, Baker A, Sinari S, Moses TY, Beckstrom-Sternberg S, Beckstrom-Sternberg J, Barrett M, Long J, Chinnaiyan A, Lowey J, Suh E, Pearson JV, Craig DW, Agus DB, Pienta KJ, Carpten JD.

Genome Res. 2011 Jan;21(1):47-55. doi: 10.1101/gr.107961.110. Epub 2010 Dec 8.

31.

Detection of androgen receptor mutations in circulating tumor cells in castration-resistant prostate cancer.

Jiang Y, Palma JF, Agus DB, Wang Y, Gross ME.

Clin Chem. 2010 Sep;56(9):1492-5. doi: 10.1373/clinchem.2010.143297. Epub 2010 Jun 25.

32.

Beta-2-microglobulin expression correlates with high-grade prostate cancer and specific defects in androgen signaling.

Mink SR, Hodge A, Agus DB, Jain A, Gross ME.

Prostate. 2010 Aug;70(11):1201-10. doi: 10.1002/pros.21155.

PMID:
20564426
33.

Cancer-associated fibroblasts derived from EGFR-TKI-resistant tumors reverse EGFR pathway inhibition by EGFR-TKIs.

Mink SR, Vashistha S, Zhang W, Hodge A, Agus DB, Jain A.

Mol Cancer Res. 2010 Jun;8(6):809-20. doi: 10.1158/1541-7786.MCR-09-0460. Epub 2010 Jun 8.

34.

HER kinase axis receptor dimer partner switching occurs in response to EGFR tyrosine kinase inhibition despite failure to block cellular proliferation.

Jain A, Penuel E, Mink S, Schmidt J, Hodge A, Favero K, Tindell C, Agus DB.

Cancer Res. 2010 Mar 1;70(5):1989-99. doi: 10.1158/0008-5472.CAN-09-3326. Epub 2010 Feb 16.

35.

Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes.

Mumenthaler SM, Ng PY, Hodge A, Bearss D, Berk G, Kanekal S, Redkar S, Taverna P, Agus DB, Jain A.

Mol Cancer Ther. 2009 Oct;8(10):2882-93. doi: 10.1158/1535-7163.MCT-09-0293.

36.

Multiparameter computational modeling of tumor invasion.

Bearer EL, Lowengrub JS, Frieboes HB, Chuang YL, Jin F, Wise SM, Ferrari M, Agus DB, Cristini V.

Cancer Res. 2009 May 15;69(10):4493-501. doi: 10.1158/0008-5472.CAN-08-3834. Epub 2009 Apr 14.

37.

Predictors of affect following treatment decision-making for prostate cancer: conversations, cognitive processing, and coping.

Christie KM, Meyerowitz BE, Giedzinska-Simons A, Gross M, Agus DB.

Psychooncology. 2009 May;18(5):508-14. doi: 10.1002/pon.1420.

PMID:
18756584
38.

Precursor-ion mass re-estimation improves peptide identification on hybrid instruments.

Luethy R, Kessner DE, Katz JE, Maclean B, Grothe R, Kani K, Faça V, Pitteri S, Hanash S, Agus DB, Mallick P.

J Proteome Res. 2008 Sep;7(9):4031-9. doi: 10.1021/pr800307m. Epub 2008 Aug 16.

39.

The current state of preclinical prostate cancer animal models.

Pienta KJ, Abate-Shen C, Agus DB, Attar RM, Chung LW, Greenberg NM, Hahn WC, Isaacs JT, Navone NM, Peehl DM, Simons JW, Solit DB, Soule HR, VanDyke TA, Weber MJ, Wu L, Vessella RL.

Prostate. 2008 May 1;68(6):629-39. doi: 10.1002/pros.20726.

40.

A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer.

Gross M, Higano C, Pantuck A, Castellanos O, Green E, Nguyen K, Agus DB.

BMC Cancer. 2007 Jul 27;7:142.

41.

Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy.

Agus DB, Sweeney CJ, Morris MJ, Mendelson DS, McNeel DG, Ahmann FR, Wang J, Derynck MK, Ng K, Lyons B, Allison DE, Kattan MW, Scher HI.

J Clin Oncol. 2007 Feb 20;25(6):675-81.

PMID:
17308272
42.

Clinical proteomics: the promises and challenges of mass spectrometry-based biomarker discovery.

deVera IE, Katz JE, Agus DB.

Clin Adv Hematol Oncol. 2006 Jul;4(7):541-9.

PMID:
17147241
43.

Raloxifene, an oestrogen-receptor-beta-targeted therapy, inhibits androgen-independent prostate cancer growth: results from preclinical studies and a pilot phase II clinical trial.

Shazer RL, Jain A, Galkin AV, Cinman N, Nguyen KN, Natale RB, Gross M, Green L, Bender LI, Holden S, Kaplan L, Agus DB.

BJU Int. 2006 Apr;97(4):691-7.

44.
45.

2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth.

Takai N, Jain A, Kawamata N, Popoviciu LM, Said JW, Whittaker S, Miyakawa I, Agus DB, Koeffler HP.

Cancer. 2005 Dec 15;104(12):2701-8.

46.

Ductal adenocarcinoma of the prostate.

Shazer RL, Luthringer D, Agus DB, Gross ME.

Clin Adv Hematol Oncol. 2004 Jun;2(6):393-5; discussion 396. No abstract available.

PMID:
16163211
47.

Update on HER-kinase-directed therapy in prostate cancer.

Gross ME, Jo S, Agus DB.

Clin Adv Hematol Oncol. 2004 Jan;2(1):53-6, 64. Review.

PMID:
16163160
48.

A perspective on protein profiling of blood.

Katz JE, Mallick P, Agus DB.

BJU Int. 2005 Sep;96(4):477-82. Review. No abstract available.

49.

Epithelial membrane protein-1 is a biomarker of gefitinib resistance.

Jain A, Tindell CA, Laux I, Hunter JB, Curran J, Galkin A, Afar DE, Aronson N, Shak S, Natale RB, Agus DB.

Proc Natl Acad Sci U S A. 2005 Aug 16;102(33):11858-63. Epub 2005 Aug 8.

50.

Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer.

Agus DB, Gordon MS, Taylor C, Natale RB, Karlan B, Mendelson DS, Press MF, Allison DE, Sliwkowski MX, Lieberman G, Kelsey SM, Fyfe G.

J Clin Oncol. 2005 Apr 10;23(11):2534-43. Epub 2005 Feb 7.

PMID:
15699478

Supplemental Content

Support Center